Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse .

A more than 35% rally in the company’s stock this year has largely been driven by the explosive growth of the weight-loss drug market.

Once seen as a niche category, obesity treatments are now one of the most lucrative segments in healthcare, with steadily rising demand.

Novo Nordisk had the early lead in the space, but Lilly’s drugs — Mounjaro and Zepbound — have surged in popularity and helped eclipse its rival in prescriptions.

The company’s shares were up 1.3% at a record high of $1,057.7.

Lilly now trades at one of the richest valuations in big pharma, at about 50 times its anticipated

See Full Page